Alan Milinazzo Net Worth

The estimated Net Worth of Alan Milinazzo is at least $362 mil dollars as of 9 July 2020. Mr. Milinazzo owns over 18,450 units of Flexion Therapeutics Inc stock worth over $210,911 and over the last 19 years he sold FLXN stock worth over $0. In addition, he makes $151,184 as Independent Director at Flexion Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Milinazzo FLXN stock SEC Form 4 insiders trading

Alan has made over 4 trades of the Flexion Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 18,450 units of FLXN stock worth $40,590 on 9 July 2020.

The largest trade he's ever made was buying 100,000 units of Flexion Therapeutics Inc stock on 3 March 2013 worth over $200,000. On average, Alan trades about 3,123 units every 60 days since 2005. As of 9 July 2020 he still owns at least 22,950 units of Flexion Therapeutics Inc stock.

You can see the complete history of Mr. Milinazzo stock trades at the bottom of the page.

Alan Milinazzo biography

Alan W. Milinazzo serves as Independent Director of the Company. Mr. Milinazzo has served as one of our directors since 2011. Mr. Milinazzo is a partner in the Global Healthcare and Life Sciences Practice at Heidrick & Struggles International, Inc., a global executive search and leadership consulting firm, a position he has held since January 2016. From 2013 to 2016, he served as President, Chief Executive Officer and a member of the board of directors of InspireMD, Inc., a publicly traded medical device company. From 2006 to 2011, Mr. Milinazzo served as president and chief executive officer of Orthofix International, N.V., a publicly traded global orthopedic company, a position he was promoted to in 2006 after initially being hired as the company’s chief operating officer in 2005. From 2002 to 2005, Mr. Milinazzo served as the General Manager of Medtronic, Inc.’s coronary and peripheral vascular businesses. He currently serves on the board of directors of CAS Medical Systems, Inc. (CASMED), a publicly traded medical technology company, and was appointed executive chairman of the board of directors of Opsens Inc. in 2019. Mr. Milinazzo formerly served on the board of directors of LDR Holding Corporation, a publicly traded medical device company from 2015 until its acquisition by Zimmer Biomet Holdings in June 2016, and on the board of directors of Orthofix International, N.V. from December 2006 until June 2012. He received his undergraduate degree from Boston College. Our Board believes that Mr. Milinazzo’s expertise in management and marketing in the pharmaceutical and medical device market and his 25 years of experience in the healthcare and life sciences sector qualifies him to serve on our Board of Directors.

What is the salary of Alan Milinazzo?

As the Independent Director of Flexion Therapeutics Inc, the total compensation of Alan Milinazzo at Flexion Therapeutics Inc is $151,184. There are 8 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.

How old is Alan Milinazzo?

Alan Milinazzo is 60, he's been the Independent Director of Flexion Therapeutics Inc since 2011. There are 5 older and 11 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.

What's Alan Milinazzo's mailing address?

Alan's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon, eSamuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.

What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.

Complete history of Mr. Milinazzo stock trades at Flexion Therapeutics Inc, Orthofix Medical Inc, eInspireMD Inc

Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Clayman,
  President, Chief Executive Officer, Director
• David Arkowitz,
  Chief Financial Officer
• Scott Kelley,
  Chief Medical Officer
• Mark Levine,
  General Counsel and Corporate Secretary
• Dr. Neil Bodick,
  Consultant
• Patrick Mahaffy,
  Independent Chairman of the Board
• Sandesh Mahatme,
  Independent Director
• Samuel Colella,
  Independent Director
• Alan Milinazzo,
  Independent Director
• Mark Stejbach,
  Independent Director
• C. Ann Merrifield,
  Independent Director
• Scott Canute,
  Independent Director
• Heath Lukatch,
  Independent Director
• Scott Young,
  IR Contact Officer
• Elizabeth Kwo,
  Director
• Christina Willwerth,
  Chief Strategy Officer
• Kerry Wentworth,
  Chief Regulatory Officer
• Melissa Layman,
  Chief Commercial Officer
• John Magee,
  VP of Sales
• Carolyn Beaty Scimemi,
  VP, Legal Affairs & Chief Compliance Officer
• David A. Arkowitz M.B.A.,
  Chief Financial Officer
• Ventures Iii, Llc Versant V...,
  
• Yamo Deniz,
  Chief Medical Officer
• Frederick W Driscoll,
  Chief Financial Officer
• Barbara N Bolzon Bradley J ...,
  
• William T. Andrews,
  Chief Medical Officer
• Utpal Koppikar,
  Director
• Neil Bodick,
  Chief Scientific Officer
• Ventures Ii Lp5 Am Co Inves...,
  
• Holdings A/S Novo,
  10% owner
• Partners Sas Sofinnova,
  10% owner
• Venture Capital Iii, L.P.Bo...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Rafael Tordjman,
  Director
• Andrew J. Schwab,
  Director
• Bradley J Ph D Bolzon,
  Director
• Venture Capital Iii, L.P.Ve...,
  
• Inc Pfizer,
  10% owner
• Management, Llc Newtyn,
  10% owner
• Adam Muzikant,
  Chief Business Officer